Multiple sclerosis and pregnancy as a significant social problem in modern neurology
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.108Keywords
pregnancy, women's health, reproductive health, mulitple sclerosis, neurologyAbstract
Along with the increasing number of reported cases, multiple sclerosis, one of the main causes of disability among young adults, is nowadays an increasingly common health problem. Considering the fact that it occurs mainly between 20 and 40 years and affects women more often, the question of the impact of the disease on pregnancy becomes obvious. In view of the wide selection of drugs for various purposes and often highly individualized forms of therapy, it seems also important to determine the safety profile of these agents in relation to the health of the pregnant woman and the fetus. All of this is a significant challenge for neurologists and obstetricians and is the subject of many research and studies. The awareness of society, especially women, in the face of the growing problem seems to be equally important. This paper summarizes the current state of knowledge on these issues.
References
„Howard J, Trevick S, Younger DS. Epidemiology of Multiple Sclerosis. Neurol Clin. 2016 Nov;34(4):919-93”.
„Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016 Jan;172(1):3-13”.
„Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 Jul;13(7):700-22”.
„Kułakowska A, Bartosik-Psujek H, Hożejowski R, et al. Selected aspects of the epide miology of multiple sclerosis in Poland – a multicentre pilot study. Neurologia i Neurochirurgia Polska. 2010;44:443–452”.
„Niino M, Miyazaki Y. [Relapsing-Remitting Multiple Sclerosis]. Brain Nerve. 2021 May;73(5):442-449”.
„Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am 2017; 27:195–204”.
„Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):193-205”.
„Anlar O. Treatment of multiple sclerosis. CNS Neurol Disord Drug Targets. 2009 Jun;8(3):167-74”.
„Aktas O, Wattjes MP, Stangel M, Hartung HP. Diagnose der Multiplen Sklerose: Revision der McDonald-Kriterien 2017 [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]. Nervenarzt. 2018 Dec;89(12):1344-1354”.
„Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016 Jun;22(6 Suppl):s141-50”.
„Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, Aslani S. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019 Jan;68(1):25-38”.
„Olek MJ. Multiple Sclerosis. Ann Intern Med. 2021 Jun;174(6)”.
„Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020 Dec;133(12):1380-1390”.
„iotti JR, Cross AH. Disease-Modifying Treatment in Progressive Multiple Sclerosis. Curr Treat Options Neurol. 2018 Apr 7;20(5):12”.
„Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40”.
„Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec;31(6):752-759”.
„Ochi H. [Epidemiology of Multiple Sclerosis: Is Multiple Sclerosis on the Rise?]. Brain Nerve. 2020 May;72(5):467-484”.
„Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014 Feb-Mar;48-49:134-42”.
„Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383”.
„Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998 Jul 30;339(5):285-91”.
„Salemi G, Callari G, Gammino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand. 2004; 110(1): 23–26”.
„Jokubaitis VG, Spelman T, Kalincik T, et al. MSBase Study Group. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016 Jul;80(1):89-100”.
„endibe Bilbao M, Boyero Durán S, Bárcena Llona J, Rodriguez-Antigüedad A. Multiple sclerosis: Pregnancy and women's health issues. Neurologia (Engl Ed). 2019 May;34(4):259-269”.
„Vukusic S, Michel L, Leguy S, Lebrun-Frenay C. Pregnancy with multiple sclerosis. Rev Neurol (Paris). 2021 Mar;177(3):180-194”.
„Varytė G, Zakarevičienė J, Ramašauskaitė D, et al. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity. Medicina (Kaunas). 2020 Jan 21;56(2):49”.
„Hellwig K, Geissbuehler Y, Sabidó M, et al.. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol 2020; 267:1715–1723”.
„Kaplan T.B. Management of Demyelinating Disorders in Pregnancy. Neurol. Clin. 2019;37:17–30”.
„Hakkarainen KM, Juuti R, Burkill S, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020 Oct 7;13:1756286420951072”.
„Neuhaus O, Kieseier BC, Hartung H-P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007; 259:27–37”.
„Hale TW, Siddiqui AA, Baker TE. Transfer of Interferon β-1a into human breastmilk. Breastfeeding Med 2011; 7:123–125”.
„Ciplea AI, Langer-Gould A, Stahl A, et al.. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: one-year infant outcomes. Neurol Neuroimmunol Neuroinflamm 2020; 7:e757”.
„EMA. Tecfidera (dimethyl fumarate) – EPAR summary of product characteristics 2014”.
„Dobson R., Dassan P., Roberts M., Giovannoni G., Nelson-Piercy C., Brex P.A. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract. Neurol. 2019;19:106–114”.
„Hellwig K, Rog D, McGuigan C, et al. An international registry tracking pregnancy outcome in women treated with dimethyl fumarate [Internet]. 2019.”.
„ Fabian M. Pregnancy in the Setting of Multiple Sclerosis. Continuum. 2016;22:837–850”.
„FDA. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation. [Internet]. 2012.”.
„Vukusic S, Coyle PK, Jurgensen S, et al.. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of postmarketing experience. Mult Scler 2020; 26:829–836”.
„Henson LJ, Afsar S, Davenport L, et al.. Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reproduct Toxicol 2020; 95:45–50”.
„Multiple Sclerosis Awareness. 2019.”.
„Bodiguel E., Bensa C., Brassat D., Laplaud D., Le Page E., Ouallet J.-C., Zephir H., De Seze J. Multiple sclerosis and pregnancy. Rev. Neurol. 2014;170:247–265”.
„Karlsson G, Francis G, Koren G, et al.. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82:674–680”.
„Pauliat E, Onken M, Weber-Schoendorfer C, et al.. Pregnancy outcome following first-trimester exposure to fingolimod: a collaborative ENTIS study. Mult Scler 2021; 27:475–478”.
„Landi D, Portaccio E, Bovis F, et al.. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. ECTRIMS Online Libr 2019; 338:279583”.
„Ciplea AI, Hellwig K. Exposure to natalizumab during pregnancy and lactation is safe – commentary. Mult Scler 2020; 26:892–893”.
„Plavina T, Muralidharan KK, Kuesters G, et al.. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017; 89:1584–1593”.
„Alroughani R., Altintas A., Al Jumah, et al. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult. Scler. Int. 2016;2016:1034912”.
„Oh J, Achiron A, Celius EG, et al.. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord 2020; 43:102146”.
„Lemtrada SPC. European Medicines Agency. 2019”.
„Decallonne B, Bartholomé E, Delvaux V, et al.. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg 2018; 118:153–159”.
„Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health 2009; 18:1847–1856”.
„Oreja-Guevara C, Wray S, Buffels R, et al.. Pregnancy outcomes in patients treated with ocrelizumab. ECTRIMS Online Library 2019; 279140:780”.
„Canibaño B, Deleu D, Mesraoua B, Melikyan G, et al.. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess 2020; 9:20–36”.
„Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun;25(3):773-792”.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Maciej Kamieniak, Natalia Wolanin, Magdalena Marzęda, Piotr Jarosz, Izabela Kobiałka, Agnieszka Blicharz, Tomasz Swatko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 374
Number of citations: 0
